Kornimate/medical-research-clean huggingface dataset:
energy deficiency and athletic performance

Conditions: Female Athlete Triad

Summary: energy availability (ea) refers to the balance between daily energy intake and exercise energy expenditure. athletically inadequate ea is defined as low energy availability (lea). energy deficits occur throughout life, from young athletes with a relative lack of energy in sports or the female athlete triad to older adults struggling with weight loss. acute and/or chronic lea can cause negative athletic and health outcomes in athletes. it is known that lea, as an energy saving mechanism, suppresses the reproductive system and causes disruption of the menstrual cycle, as well as causing many interrelated endocrine-related physiological consequences by changing other hormonal pathways. menstrual dysfunction due to lea causes various risks as it can disrupt the ec during training and competition. therefore, low ea may contribute to poor sports performance due to detrimental endocrine effects. various parameters such as body mass and nutritional intake affect the performance of athletes, and lea is frequently reported among athletes with intense training programs. lea combined with high training volumes; it can cause negative consequences such as impaired protein synthesis/degradation rate, impaired hormonal and training response, increased risk of fatigue, and these can lead to decreased performance. resting metabolic rate, which indicates the energy expended for basic body functions, is considered a potential objective indicator of energy availability. regulation of dietary energy intake in the management of lea in athletes covers a wide area in the literature. however, lea is caused not only by a deficiency in energy intake but also by an excess in energy expenditure. in the light of this information, the aim of the study is to examine the acute period effects of the training program in which exercise energy expenditure is reduced in terms of energy availability and athletic performance.

voluntary participants who have been diagnosed with energy deficiency will be included in the study. signed voluntary consent will be obtained from participants. participants will be divided into two groups. study groups will be as follows: a) modified training, b) routine training.

Eligibility criteria:
inclusion criteria: * 18- 35 years old female gender * body mass index being less than 18.50-24.99 kg/m2 * having a energy deficiency * been interested in basketball professionally for at least one year * must be training with the team at least 3 days a week * performance levels should be 3-4 exclusion criteria: * having a history of any fracture in the last year * having had a sports injury in the last 8 months * having had an infectious disease in the last 6 months being a smoker * getting 2 or more points from the scoff survey * having been using any medication regularly for the last 6 months

Keywords: energy deficiency eccentric exercise athletic performans
bioequivalence study of torrent pharmaceuticals ltd's pioglitazone hydrochloride and metformin hydrochloride tablets under fed conditions

Conditions: Healthy

Summary: objective: subjects to compare the single dose bioavailability of torrent's pioglitazone hydrochloride and metformin hydrochloride tablets 15 mg/850 mg and actoplus met® (pioglitazone hydrochloride and metformin hydrochloride) tablets 15 mg/850 mg of takeda pharmaceuticals america, inc. usa. dosing periods of studies were separated by a washout period of 14 days. study design: randomized, two-way crossover, single-dose, and open-label


Eligibility criteria:
inclusion criteria: the volunteers were included in the study based on the following criteria: * sex: male. * age: 18 - 45 years. * volunteer with bmi of 18-27 (inclusive both) kg/m2 with minimum of 50 kg weight. * healthy and willing to participate in the study. * volunteer willing to adhere to the protocol requirements and to provide written informed consent. * non-smokers or smoker who smokes less than 10 cigarettes per day exclusion criteria: the volunteers were excluded from the study based on the following criteria: * clinically relevant abnormalities in the results of the laboratory screening evaluation. * clinically significant abnormal ecg or chest x-ray. * systolic blood pressure less than 100 mm hg or more than 140 mm hg and diastolic blood pressure less than 60 mm hg or more than 90 mm hg. * pulse rate less than 50/minute or more than 100/minute. oral temperature less than 95°p or more than 98.6°p. * respiratory rate less than 12/minute or more than 20/minute * history of allergy to the test drug or any drug chemically similar to the drug under investigation. * history of alcohol or drug abuse * positive breath alcohol test * recent history of kidney or liver dysfunction. * history of consumption of prescribed medication since last 14 days or otc medication since last 07 days before beginning of the study. * volunteers suffering from any chronic illness such as arthritis, asthma etc. * history of heart failure. * hiv, hcv, hbsag positive volunteers. * opiate, tetra hydrocannabinol, amphetamine, barbiturates, benzodiazepines,cocaine positive volunteers based on urine test. * volunteers suffering from any psychiatric (acute or chronic) illness requiring medications. * administration of any study drug in the period 0 to 3 months before entry to the study. * history of significant blood loss due to any reason, including blood donation in the past 3 months. * history of pre-existing bleeding disorder. * existence of any surgical or medical condition, which, in the judgment of the chief investigator and/or clinical investigator/physician, might interfere with the absorption, distribution, metabolism or excretion of the drug or likely to compromise the safety of volunteers. * inability to communicate or co-operate due to language problem, poor mental development or impaired cerebral function.
safety and tolerability of aclidinium bromide/formoterol fumarate compared with formoterol fumarate in patients with moderate to severe chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to assess the long-term safety and tolerability of inhaled aclidinium bromide/formoterol in patients with moderate to severe, stable chronic obstructive pulmonary disease (copd).


Eligibility criteria:
inclusion criteria: * current or former cigarette smokers with a cigarette smoking history of at least 10 pack-years * a diagnosis of stable moderate to severe copd and stable airway obstruction as defined by the global initiative for chronic obstructive lung disease guidelines and stable airway obstruction. exclusion criteria: * patients who have been hospitalized for an acute copd exacerbation within three months prior to visit 1 * any respiratory tract infection (including the upper respiratory tract) or copd exacerbation in the six weeks before visit 1. * patients with any clinically significant respiratory conditions other than copd * clinical history that suggests that the patient has asthma as opposed to copd * chronic use of oxygen therapy ≥ 15 hours/day * patients with clinically significant cardiovascular conditions * patients with uncontrolled infection that may place the patient at risk resulting from human immunodeficiency virus (hiv), active hepatitis and/or patients with diagnosed active tuberculosis * patients with a history of hypersensitivity reaction to inhaled anticholinergics, * patients with stage ii hypertension, defined as systolic pressure of 160 and above, and/or diastolic pressure of 100 and above * current diagnosis of cancer other than basal or squamous cell skin cancer

Keywords: copd chronic obstructive pulmonary disease chronic bronchitis emphysema airflow obstruction, chronic chronic airflow obstruction chronic obstructive airway disease chronic obstructive lung disease
optic capture without anterior vitrectomy in pediatric cataract surgery

Conditions: Cataract, Juvenile

Summary: purpose: to compare two pediatric cataract surgery procedures: intraocular lens (iol) optic capture without anterior vitrectomy (av) and in-the-bag iol implantation with av. setting: ege university medical school hospital, izmir, turkey. design: prospective randomized control clinical trial. methods: patients were randomly assigned to two groups: optic capture without av (group 1) or in-the-bag implantation with av (group 2). the following variables were compared: visual acuity, intraocular pressure, refractive errors, iol tilt and decentration, lenticular astigmatism, anterior-posterior synechia, inflammatory cell deposits on iol and post-operative complications.


Eligibility criteria:
inclusion criteria: * children with congenital or developmental cataracts who had cataract surgery and primary iol implantation at a tertiary care referral institute were included. exclusion criteria: * traumatic or uveitic cataract, corneal opacity, iris coloboma, microphthalmia, microcornea, persistent fetal vascularization, congenital glaucoma, and retinopathy of prematurity were all considered exclusion criteria.

Keywords: cataract surgery; intraocular lens; optic capture; pediatric cataract; posterior capsulotomy
quantum menstrual health monitoring study

Conditions: Menstrual Cycle Abnormal; Polycystic Ovary Syndrome; Athletes

Summary: the quantum menstrual health monitoring study will measure four key reproductive hormones in the urine to characterize patterns that predict and confirm ovulation, referenced to serum hormones and the gold-standard of the ultrasound day of ovulation in participants with regular cycles. these normal cycles will provide a reference for comparison to irregular cycles in polycystic ovarian syndrome (pcos) and athletes. clinical signs in the menstrual cycle (e.g. menstrual bleeding, temperature) as well as vital sign and sleep patterns will also be referenced to hormonal changes.


Eligibility criteria:
inclusion criteria: * regularly menstruating, pcos or athlete participants aged 18-45 * negative pregnancy test at the beginning and at the end of each cycle * cycle lengths 24-34 days * knowledge of previous 3 cycle lengths * able to travel to calgary clinic for regular ultrasounds during the study period exclusion criteria: * for regular cycles * anovulation in the last 3 cycles * currently or in the previous 3 months, on medications that are known to impair or stimulate ovulation (e.g. oral contraceptives, ovulation stimulants, etc) * known conditions that impair ovulation or fertility: polycystic ovarian syndrome, endometriosis, pelvic inflammatory disease in the last year, pituitary adenomas, exclusively breastfeeding * previous surgeries impacting the menstrual cycle: hysterectomy, bilateral oophorectomy * currently pregnant * for pcos and athlete groups: * currently or in the previous 3 months, on medications that are known to impair or stimulate ovulation (e.g. oral contraceptives, ovulation stimulants, etc) * known conditions that impair ovulation or fertility: pelvic inflammatory disease in the last year, pituitary adenomas, exclusive breastfeeding * previous surgeries impacting the menstrual cycle: hysterectomy, bilateral oophorectomy * currently pregnant

Keywords: quantitative urinary hormones follicle-stimulating hormone luteinizing hormone estrone-3-glucuronide pregnanediol glucuronide ultrasound
study on the psychotherapeutic treatment of chronic nightmares

Conditions: Nightmare Disorder

Summary: the purpose of this study is to determine whether a change in the content of nightmares is necessary at all in the treatment of chronic nightmares or if a single confrontation with their content is sufficient to reduce nightmare frequency significantly.

the inclusion and exclusion criteria are assessed during a telephone interview. if the participants meet the criteria, they are randomly assigned to two intervention groups or an active control group. in the first session the participants who suffer from chronic nightmares are interviewed using the structured clinical interview for dsm-iv (scid-i and -ii) to determine the clinical diagnosis; in addition, they are given questionnaires and record sheets to obtain baseline data. they are asked to record their nightmares in a "dream diary" up until the next session four weeks later. at that session they learn one of three interventions to reduce nightmares. the first group receives imagery rehearsal treatment in which participants learn to consciously alter the contents of their nightmares and then to visualize the new set of images. the second group is subjected to confrontation treatment in which they are instructed to confront their nightmares until habituation. the third group, the psychotherapeutic placebo group, just learn an imagination technique, without reference to their nightmares. at the end of the intervention session all participants receive written instructions on how to perform the learned method at home. they must also record their dreams up until the next session. that session and the last one are used for data acquisition. at these sessions, the participants are asked to fill in the questionnaires given to them at the beginning of the treatment.

Eligibility criteria:
inclusion criteria: * nightmare frequency of at least one night per week for six month duration * stable medication * if currently in psychotherapy: no treatment of nightmares * informed consent exclusion criteria: * life time clinical diagnosis of schizophrenia, schizoaffective disorder or bipolar disorder according to dsm-iv * body mass index \< 17 * initiation of nightmares after taking pharmaceuticals * clinical diagnosis of alcohol or drug addiction according to dsm-iv * mental retardation

Keywords: chronic nightmare sufferers nightmares imagery rehearsal therapy irt sleep disturbance treatment of nightmares confrontation people who suffer of chronic nightmares
evaluation of low dose corticosteroids efficiency, associated with myfortic ® in the treatment of nephrotic syndrome

Conditions: Nephrotic Syndrome

Summary: a multicenter, randomized, study will be performed to evaluate the efficacy of low dose steroid combined with mycophenolic acid (myforticr) versus high dose steroid in inducing remission in adults with minimal change nephrotic syndrome (mcns). one hundred and fourteen patients (cpp decision 2009-04-02-a5) will be included in this study. they will be randomly assigned to an open label treatment with either prednisone 1 mg/kg/day (arm a) or 0,5 mg/kg/day plus myforticr 1440 mg/day (arm b) for four weeks. the outcome will be compared during one-year follow up

the treatment for minimal change nephrotic syndrome (mcns) is empirically based on high dose steroid. however, the side effects in adult patients are often significant and induce a lot of complications. this prospective study aimed to compare low dose steroid combined with mycophenolic acid (myforticr) versus high dose steroid in the treatment of the first episode of mcns. treatment plan after baseline evaluation including clinical biological and histological analyses, all eligible patients will be an open label assigned to two groups: group a: patients will receive prednisone 1 mg/kg/day for 4 weeks. then, the dose will be progressively tapered if the remission will be achieved. for patients who exhibit incomplete remission at this time, high dose steroid will be continued for 4 weeks again before the tapering. group b: patients will receive prednisone 0.5 mg/kg/day combined with mycophenolic acid (myforticr) 1440 mg/day. the management of steroid therapy will be identical in both groups, while myforticr will be continued for six months. in both groups, patients who will not achieve remission after 8 weeks of steroid therapy at full dose will be excluded from the study. statistical analysis in this multicenter, randomized trial, the primary and secondary end points will be the rate of complete remission within 4 and 8 weeks of the start of induction therapy, respectively.

Eligibility criteria:
inclusion criteria: * idiopathic nephrotic syndrome * flare of idiopathic syndrome without treatment from one year * confirming by renal biopsy exclusion criteria: * secondary nephrotic syndrome * pregnancy * focal segmental glomerular sclerosis lesion in the biopsy * neutropenia \< 2000/mm3 * hb\<9gr/dl

Keywords: minimal change nephrotic syndrome complete remission myfortic minimal change disease
substitution of acetate by citrate in the bicarbonate based hemodialysis

Conditions: End Stage Renal Disease (ESRD)

Summary: acetate is the primary acidifying solution used in bicarbonate-based hemodialysis worldwide. it has been published in small trials or case series that the addition of acetate is associated with a rise in nitric oxide production of vascular smooth muscle cells, endothelial cells and myocardial cells as a sign of vascular dysfunction. furthermore clinical side effects of dialysis e.g. nausea, malnutrition, intradialytic blood pressure drops, induction of proinflammatory cytokines and activation of complement and leukocytes have been described with acetate. citrate on the other hand was associated with: acid-base disorders (metabolic alkalosis), disturbances of the calcium homeostasis (hypocalcemia), but also anti-inflammatory effects. both dialysate additives (citrate and acetate) are commercially available and are used world wide in dialysis centers. the investigators hypothesize that substitution of acetate by citrate reduces the cardiovascular risk (measured by a change in the surrogate parameter of pulse wave velocity and augmentation index) and might improves quality of life in the participants. furthermore the investigators speculate that citrate in the dialysis solution could reduce systemic inflammation in the participants of the study.


Eligibility criteria:
inclusion criteria: * time since initiation of dialysis \> 3 months * age \> 18 years * dialysis 3x/week for \> 4 hrs exclusion criteria: * ongoing infection * pregnancy * lack of written and informed consent
death rate in anesthesia: a study in a tertiary hospital

Conditions: Sudden Death

Summary: death rate in anesthesia is one of the most valuable methods to assess the safety of anesthesia practice among different types of patients. in the investigators study, the investigator will review the death rate in anesthesia whether regional or general over the past five years from 2010 to 2014, by examining the patients records from the hospital database.

death rate in anesthesia is one of the most valuable methods to assess the safety of anesthesia practice among different types of patients. most of the studies of death rate in anesthesia are retrospective. although retrospective studies suffer many draw backs in their design and results, but they are still common method to evaluate the safety of anesthesia practice for surgical patients. in the investigators study, the investigators will review the death rate in anesthesia whether regional or general over the past five years from 2010 to 2014, by examining the patients records from the hospital database. the cause of death will be grouped into: totally anesthesia related, partially anesthesia related, surgery related or patient condition related. the records and files of dead patients will be examined by committee from the researchers to estimate the cause of death. the end point of the investigators study will be anesthesia death rate inside the hospital.

Eligibility criteria:
inclusion criteria: * patients who underwent anesthesia and surgery. * patients who died inside the hospital. exclusion criteria: * patient who underwent anesthesia and surgery and do not died and discharged home. * patients who died outside the hospital.

Keywords: anesthesia mortality
expanded access to cefiderocol for the intravenous treatment of severe gram negative bacterial infections

Conditions: Bacterial Infections

Summary: expanded access may be provided for cefiderocol for qualified patients who have limited treatment options and are not eligible for a clinical trial.


Eligibility criteria:
hospitalized patients with serious gram-negative bacterial infections and who have limited treatment options and are not eligible for a clinical trial.

Keywords: s-649266 cefiderocol gram-negative
the effects of exercise training on the health-related fitness of colon cancer survivors

Conditions: Colonic Neoplasms

Summary: recent studies have suggested that individuals diagnosed with colon cancer who are inactive and/or overweight, may have poorer survival outcomes. exercise training has been shown to improve fitness and body composition in other cancer survivor groups. the investigators hypothesize that an exercise training program will be a safe, feasible, and effective intervention to improve the fitness and body composition of a group of colon cancer survivors.


Eligibility criteria:
inclusion criteria: * histologically confirmed stage ii or iii colon cancer diagnosis * less than or equal to 1 year since the completion of all adjuvant treatment * negative physical activity readiness questionnaire (par-q) or completed physical activity readiness medical examination (parmed-x) form * 18 years of age or older * ability to understand and provide written informed consent in english * willingness to be randomized * willingness to complete outcome measures at each assessment time point * available for the duration of study intervention period * able to travel to our fitness centre 3/week for the study period exclusion criteria: * any absolute contraindication to to exercise testing or training * evidence of active disease (metastatic, recurrent, or unresectable colon cancer) * any uncontrolled medical condition or psychiatric illness that would prevent completion of the exercise program or interfere with the study assessments

Keywords: colonic neoplasms aerobic exercise weight lifting body composition